Exicure Appoints New Director to Board
Ticker: XCUR · Form: 8-K · Filed: Jun 10, 2025 · CIK: 1698530
| Field | Detail |
|---|---|
| Company | Exicure, Inc. (XCUR) |
| Form Type | 8-K |
| Filed Date | Jun 10, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-appointment, management-change
TL;DR
Exicure adds Dr. David J. Earp to its board, effective June 6, 2025.
AI Summary
Exicure, Inc. announced on June 6, 2025, a change in its board of directors. Specifically, Dr. David J. Earp has been appointed as a new Class II director, effective immediately. This appointment is part of the company's ongoing efforts to strengthen its leadership team.
Why It Matters
The addition of a new director can signal strategic shifts or a focus on specific areas of expertise, potentially impacting the company's future direction and shareholder value.
Risk Assessment
Risk Level: low — The filing reports a routine board appointment, which typically carries low risk.
Key Players & Entities
- Exicure, Inc. (company) — Registrant
- Dr. David J. Earp (person) — Appointed Class II director
- June 6, 2025 (date) — Effective date of appointment
FAQ
Who was appointed to the board of directors at Exicure, Inc.?
Dr. David J. Earp was appointed as a new Class II director.
When was the appointment of Dr. David J. Earp effective?
The appointment was effective as of June 6, 2025.
What class of director was Dr. David J. Earp appointed as?
Dr. David J. Earp was appointed as a Class II director.
What is the primary business of Exicure, Inc.?
Exicure, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
What is the principal executive office address for Exicure, Inc.?
The principal executive offices are located at 400 Seaport Court, Suite 102, Redwood City, CA 94063.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 10, 2025 by Dr. David J. Earp regarding EXICURE, INC. (XCUR).